Analysis of prognosis and disease progression after local recurrence of melanoma

Cancer

Volumn 88, Issue 5, 2000, Pages 1063-1071

  Dong, Xiang O ^a   Tyler, Douglas ^a   Johnson, Jeffrey L ^a   DeMatos, Pierre ^a   Seigler, Hilliard F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Disease free interval; Local recurrence; Melanoma; Melanoma metastasis

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENDER; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; ULCER;

AGED; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 0034163246     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000301)88:5<1063::AID-CNCR17>3.0.CO;2-E     Document Type: Article

References (41)

1. Cruse CW, Wells KE, Schroer KR, Reintgen DS. Etiology and prognosis of local recurrence in malignant melanoma of the skin. Ann Plast Surg 1992;28:26-8.
2. Urist MM, Balch CM, Soong SJ, Shaw HM, Milton GW, Maddox WA. The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer 1985; 55:1398-1402.
3. Cohn-Cedermark G, Månsson-Brahme E, Rutqvist LE, Larsson O, Johansson H, Ringborg U. Outcomes of patients with local recurrence of cutaneous malignant melanoma: a population-based study. Cancer 1997;80:1418-25.
4. Griffiths RW, Briggs JC. Incidence of locally metastatic ('recurrent') cutaneous malignant melanoma following conventional wide margin excisional surgery for invasive clinical stage I tumours: importance of maximal primary tumour thickness. Br J Surg 1986;73:349-53.
5. Soong S, Harrison RA, McCarthy WH, Urist MM, Balch C. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol 1998;67: 228-33.
6. Reintgen DS, Cox C, Slingluff CL, Seigler HF. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg 1992;28:45-9.
7. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
8. Crowley NJ, Seigler HF. Relationship between disease-free interval and survival in patients with recurrent melanoma. Arch Surg 1992;127:1303-8.
9. Crowley NJ, Seigler HF. Late recurrence of malignant melanoma: analysis of 168 patients. Ann Surg 1990;212:173-7.
10. Kelly JW, Sagebiel RW, Calderon W, Murillo L, Dakin RL, Blois MS. The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma. Ann Surg 1984;200:759-63.
11. Brown CD, Zitelli JA. The prognosis and treatment of true local cutaneous recurrent malignant melanoma. Dermatol Surg 1995;21:285-90.
12. Cascinelli N, Bufalino R, Marolda R, Belli F, Nava M, Galluzzo D, et al. Regional non-nodal metastases of cutaneous melanoma. Eur J Surg Oncol 1986;12:175-80.
13. Day CL, Harrist TJ, Gorstein F, Sober AJ, Lew RA, Friedman RJ, et al. Malignant melanoma: prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg 1981;194:108-12.
14. Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: long-term results of the multi-institutional randomized surgical trial. Ann Surg Oncol 1996;3:446-52.
15. Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera D, Bardruk A, et al. Thin stage I primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988;318:1159-62.
16. Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm): results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218:262-9.
17. Ringborg U, Andersson R, Eldh J, Galumann B, Hafstrom L, Jacobsson S, et al. Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: a randomized study by the Swedish melanoma study group. Cancer 1996;77:1809-14.
18. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
19. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
20. Demicheli R, Terenziani M, Valagussa P, Moliterni A, Zambetti M, Bonadonna G. Local recurrences following mastectomy: support for the concept of tumor dormancy. J Natl Cancer Inst 1994;86:45-8.
21. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
22. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-53.
23. Shaw HM, Beattie CW, McCarthy WH, Milton GW. Late relapse from cutaneous stage I malignant melanoma. Arch Surg 1985;120:1155-9.
24. Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 1997;79:2361-70.
25. Barnhill RL, Piepkorn MW, Cochran AJ, Flynn E, Karaoli T, Folkman J. Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases. Arch Dermatol 1998;134:991-4.
26. Roses DF, Harris MN, Rigel D, Carrey Z, Friedman R, Kopf AW. Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma. Ann Surg 1983;198:65-9.
27. Reintgen DS, Vollmer R, Tso CY, Seigler HF. Prognosis for recurrent stage I malignant melanoma. Arch Surg 1987;122: 1338-42.
28. Karakousis CP, Temple DF, Moore R, Ambrus JL. Prognostic parameters in recurrent malignant melanoma. Cancer 1983; 52:575-9.
29. Balch CM, Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, Maddox WA. The prognostic significance of ulceration of cutaneous melanoma. Cancer 1980;45:3012-7.
30. Karakousis CP, Bartolucci AA, Balch CM. Local recurrences and its management. In: Balch CM, Houghton AN, Sober AJ, Soong SJ. Cutaneous melanoma. 3rd edition. St. Louis: Quality Medical Publishing, Inc., 1998:155-62.
31. Yeung RSW. Recurrent cutaneous melanoma: a surgical perspective. Semin Oncol 1993;20:400-18.
32. Krementz ET, Carter RD, Sutherland CM, Muchmore JH, Ran RF, Creech O Jr. Regional chemotherapy for melanoma: a 35-year experience. Ann Surg 1994;220:520-35.
33. Sugarbaker EV, McBride CM. Survival and regional disease control after isolation-perfusion for invasive stage I melanoma of the extremities. Cancer 1976;37:188-98.
34. Reintgen DS, Cruse CW, Wells KE, Saba HI, Slingluff CL Jr. Isolated limb perfusion for recurrent melanoma of the extremity. Ann Plast Surg 1992;28:50-4.
35. Creech O, Krementz ET, Ryan RF, Winbald JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616-32.
36. Stehlin JS, Giovanella BC, de Ipolyi PD, Anderson RF. Eleven years' experience with hyperthermic perfusion for melanoma of the extremities. World J Surg 1979;3:305-7.
37. Brobeil A, Berman C, Cruse CW, De Conti R, Cantor A, Lyman GH, et al. Efficacy of hyperthermic isolated limb perfusion for extremity-confined recurrent melanoma. Ann Surg Oncol 1998;5:376-83.
38. Feldman AL, Alexander HR, Bartlett DL, Fraker DL, Libutti SK. Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol 1999;6:562-7.
39. Bryant PJ, Balderson GA, Mead P, Egerton WS. Hyperthermic isolated limb perfusion for malignant melanoma: response and survival. World J Surg 1995;19:363-8.
40. Klopp CT, Bateman J, Berry N, Alford C, Winship T. Fractionated regional cancer chemotherapy. Cancer Res 1950;10: 229.
41. Markowitz JS, Cosimi LA, Carey RW, Kang S, Padyk C, Sober AJ, et al. Prognosis after initial recurrence of cutaneous melanoma. Arch Surg 1991;126:703-8.